BridgeBio (BBIO): A Tactical Long on Oncology Optionality After the Selloff
BridgeBio trades well below its 52-week high despite multiple near-term regulatory catalysts and improving commercial traction for Attruby. The company is unprofitable and levered to execution, but the current price - combined with heavy short interest and constructive technicals - creates a defined-reward trade for investors willing to tolerate bi…